Last reviewed · How we verify
Treatment Prevention for Secondary CV
Treatment Prevention for Secondary CV is a PCSK9 inhibitor Small molecule drug developed by Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III. It is currently in Phase 3 development for Secondary cardiovascular prevention in patients with established cardiovascular disease or atherosclerotic cardiovascular disease. Also known as: Antiplatelet agents, Lipid Lowering Agents, Renin-angiotensin-aldosterone system blockers.
This drug targets the PCSK9 protein to lower LDL cholesterol levels.
This drug targets the PCSK9 protein to lower LDL cholesterol levels. Used for Secondary cardiovascular prevention in patients with established cardiovascular disease or atherosclerotic cardiovascular disease.
At a glance
| Generic name | Treatment Prevention for Secondary CV |
|---|---|
| Also known as | Antiplatelet agents, Lipid Lowering Agents, Renin-angiotensin-aldosterone system blockers |
| Sponsor | Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III |
| Drug class | PCSK9 inhibitor |
| Target | PCSK9 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
By inhibiting PCSK9, the drug increases the number of LDL receptors on the liver surface, leading to increased clearance of LDL cholesterol from the bloodstream. This results in a reduction of circulating LDL cholesterol levels, which can help prevent cardiovascular events.
Approved indications
- Secondary cardiovascular prevention in patients with established cardiovascular disease or atherosclerotic cardiovascular disease
Common side effects
- Injection site reactions
- Musculoskeletal pain
- Diarrhea
- Nausea
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Treatment Prevention for Secondary CV CI brief — competitive landscape report
- Treatment Prevention for Secondary CV updates RSS · CI watch RSS
- Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III portfolio CI
Frequently asked questions about Treatment Prevention for Secondary CV
What is Treatment Prevention for Secondary CV?
How does Treatment Prevention for Secondary CV work?
What is Treatment Prevention for Secondary CV used for?
Who makes Treatment Prevention for Secondary CV?
Is Treatment Prevention for Secondary CV also known as anything else?
What drug class is Treatment Prevention for Secondary CV in?
What development phase is Treatment Prevention for Secondary CV in?
What are the side effects of Treatment Prevention for Secondary CV?
What does Treatment Prevention for Secondary CV target?
Related
- Drug class: All PCSK9 inhibitor drugs
- Target: All drugs targeting PCSK9
- Manufacturer: Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Secondary cardiovascular prevention in patients with established cardiovascular disease or atherosclerotic cardiovascular disease
- Also known as: Antiplatelet agents, Lipid Lowering Agents, Renin-angiotensin-aldosterone system blockers
- Compare: Treatment Prevention for Secondary CV vs similar drugs
- Pricing: Treatment Prevention for Secondary CV cost, discount & access